Overview of Cyclopan

What is Cyclopan? Definition and Core Classification

Property	Description
Active Ingredients	Dicycloverine (Dicyclomine) and Paracetamol (Acetaminophen)
Form	Oral tablet, Oral solution/syrup, Injection
Pharmacological Class	Spasmolytic Analgesic (Combination Medicine)
General Purpose	Relief of visceral cramps and associated abdominal pain
Origin	Synthetic

Cyclopan is defined as a synthetic combination drug specifically created to address acute pain and painful spasms, particularly those stemming from the gastrointestinal system. It is classified pharmacologically as a Spasmolytic Analgesic, signifying its dual function in providing both muscle relaxation and pain reduction. This preparation is a fixed-dose combination containing two distinct active ingredients: Dicycloverine Hydrochloride (an antispasmodic and anticholinergic agent) and Paracetamol (an analgesic and antipyretic agent).

The Dicycloverine component's function is centered on providing smooth muscle spasm relief by acting on the muscles of the gut. This mechanism shows the medicine’s primary role is to ease the physical tightening of internal muscles. The dual composition provides a simultaneous approach to managing both the cramp and the resulting pain sensation.

Composition: A Dual-Action Spasmolytic Analgesic

The medication's core benefit stems from its dual mechanism. Dicycloverine works to inhibit involuntary contractions that cause cramping. By blocking certain chemical signals in the gut, it provides targeted relief from the spasm itself. This action is complemented by Paracetamol, which provides central pain relief by helping to reduce the body's perception of pain signals, thereby lessening the discomfort resulting from the cramp.

This combination is particularly useful in managing visceral pain, which is often characterized by cramping. Dicycloverine, as part of its class, is used to reduce functional gastrointestinal discomfort.

Available Forms and General Benefit

To facilitate flexible treatment, Cyclopan is manufactured in several common dosage forms, including the standard oral tablet, an oral solution (syrup or drops), and, in certain contexts, an intramuscular (IM) injection. The general purpose of this combination medicine is to alleviate acute, painful visceral cramps and associated abdominal discomfort. The availability of multiple formats (oral route and intramuscular route) is a key differentiating feature, ensuring that patients have access to the medication, facilitating the essential relaxation of affected internal smooth muscles.

Regulatory References

What side effects are possible with Cyclopan?

Possible Side Effects and Safety Information

Cyclopan, as a fixed-dose combination containing an antispasmodic (Dicycloverine) and an analgesic (Paracetamol), has documented safety profiles reflecting the actions of both active ingredients. Safety classifications and reported adverse reactions are based strictly on official regulatory labeling.

Documented Adverse Reactions and Frequencies

The most common adverse reactions reported for the Dicycloverine component included effects such as dizziness, dry mouth, blurred vision, nausea, somnolence (drowsiness), and asthenia (weakness). Other reported effects, which may not have a defined frequency, span the Nervous System (e.g., headache, confusion, psychosis) and Gastrointestinal System (e.g., constipation, vomiting).

The Paracetamol component is associated with very rare risks of blood and lymphatic system disorders, including thrombocytopenia (low platelet count) and leucopenia. Hypersensitivity reactions such as rash and urticaria have also been reported.

Serious Adverse Reactions and Systemic Safety Patterns

Serious adverse reactions associated with the combination primarily involve two areas. The Paracetamol component carries the risk of hepatotoxicity potentially leading to acute liver failure, and severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS). For Dicycloverine, serious documented concerns include the potential for toxic megacolon in patients with severe ulcerative colitis and serious respiratory/CNS collapse, particularly in infants.

Population-Specific Safety Considerations

Official documents highlight that the Dicycloverine component is contraindicated in infants less than six months of age due to the reported occurrence of severe respiratory and central nervous system effects. Older adults may be more susceptible to CNS adverse events like confusion and agitation. Both active ingredients require caution in patients with existing hepatic or renal disease.

Overdose and Emergency Response

Overdose and when to seek help

The overdose profile for Cyclopan addresses the distinct toxicities of its two components as described in official regulatory prescribing information. Any potential overdose requires immediate attention.

Documented Overdose Manifestations

Overdose of the Paracetamol component may initially present with non-specific symptoms such as nausea, vomiting, pallor, and abdominal pain. A critical regulatory concern is that severe outcomes, including hepatic cytolysis, acute renal failure, encephalopathy, coma, and death, may be significantly delayed. Dicycloverine overexposure is associated with anticholinergic signs, including dilated pupils (mydriasis), hot dry skin, blurred vision, headache, confusion, and Central Nervous System stimulation.

Required Emergency Actions

Regulatory documents mandate that prompt medical attention is critical. Individuals must seek immediate medical attention or contact a Poison Control Center right away, even if the patient feels well, due to the potential for irreversible liver damage. The management of Paracetamol toxicity requires the use of Acetylcysteine, the specific antidote, which is indicated to prevent or lessen hepatic injury. Supportive measures, including symptomatic treatment and laboratory monitoring of liver function, are required. Population-specific considerations note that patients with underlying liver disease or chronic alcoholism, as well as geriatric patients, may be at increased risk for severe manifestations.

Therapeutic Uses of Cyclopan

What Cyclopan treats: main uses and benefits

Cyclopan is a medication primarily used to manage symptoms related to gastrointestinal motility disorders and smooth muscle spasms. It belongs to a class of drugs known as antispasmodics, which work by relaxing the muscles in the stomach and intestines.

Therapeutic Indications

The medication is most commonly used for the following conditions:

Irritable Bowel Syndrome (IBS): It helps alleviate the abdominal pain, bloating, and cramping associated with IBS by reducing excessive muscular contractions in the gut.
Gastrointestinal Spasms: It is used to treat acute spasms of the digestive tract, providing relief from discomfort caused by involuntary muscle tightening.
Functional Bowel Disorders: It may be used to manage various functional disturbances of the digestive system where muscle overactivity is a primary factor.

Mechanisms and Benefits

The primary benefit of Cyclopan is its ability to restore more normal movement to the digestive system. By targeting the smooth muscle cells, the medication helps to:

Reduce Pain: By easing muscle spasms, it directly addresses the source of cramping and sharp abdominal pain.
Improve Comfort: It helps reduce the sensation of pressure and bloating often felt during digestive episodes.
Regulate Motility: It aids in stabilizing the transit time of contents through the digestive tract by preventing erratic muscle contractions.

While the medication is effective for symptom management, it is designed to address the physical manifestations of muscle hyperreactivity rather than treating an underlying infection or structural abnormality.

Eligibility and Restrictions for Use

Who Can and Cannot Use Cyclopan? Official Regulatory Information

The eligibility for Cyclopan, a combination medicine containing Dicycloverine and Paracetamol, is governed by official regulatory documentation that defines specific populations who must avoid the drug or use it under restricted conditions. These rules are primarily based on the effects of the anticholinergic component, Dicycloverine.

Absolute Contraindications

Population Group or Condition	Regulatory Status
Infants under 6 months of age	Contraindicated
Nursing mothers (Lactation)	Contraindicated
Severe Hepatic Impairment/Liver Disease	Contraindicated
Glaucoma or Myasthenia Gravis	Contraindicated
Obstructive Diseases (GI tract, Urinary Uropathy)	Contraindicated

Restrictions and Conditional Use

Certain populations must use Cyclopan with caution or are subject to limitations as defined by labeling:

Pediatric Patients: Safety and effectiveness have generally not been established for the Dicycloverine component.
Older Adults (≥ 65 years): Must be used with caution due to increased sensitivity to anticholinergic side effects.
Pregnancy: Use is permitted only if clearly needed and the benefit outweighs the potential risk.
Renal or Cardiovascular Conditions: Use requires caution in patients with severe renal impairment or conditions like cardiac tachyarrhythmia or coronary heart disease.

These eligibility rules strictly define the approved and prohibited patient groups, ensuring adherence to the official constraints established by regulatory authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation defines Cyclopan's interaction profile based on the dual pharmacology of its Dicycloverine and Paracetamol components. These constraints impose mandatory restrictions and requirements for co-administration.

Interaction Classifications

Contraindicated Combinations: Co-administration with other Acetaminophen-containing products is formally restricted due to the established risk of severe liver damage (hepatotoxicity) from cumulative exposure. The combination with Pramlintide is also contraindicated based on documented synergistic inhibition of gastrointestinal motility. Dicycloverine's activity contraindicates its use with certain antiglaucoma treatments.
Pharmacodynamic Effects: Cyclopan may exhibit additive anticholinergic effects when taken with other Anticholinergic Agents (e.g., antihistamines). Its anti-motility effect can also cause pharmacodynamic antagonism to medicines that enhance gastrointestinal movement, such as Metoclopramide.
Exposure Modification: Prolonged regular daily use of the Paracetamol component may enhance the effect of Warfarin and other Coumarins, creating a clinically significant bleeding risk that requires regulatory monitoring. Dicycloverine can slow the absorption of slowly dissolving forms of Digoxin, potentially resulting in an increased concentration of Digoxin in the blood.
Timing and Substance-Related Notes: The regulatory information advises avoiding simultaneous use with Antacids to prevent the reduced absorption of the Dicycloverine component. The risk of severe liver damage from the Paracetamol component is significantly increased if alcohol is consumed chronically while using this product. The elderly population and patients with hepatic or renal disease are officially noted as having an increased susceptibility to interaction-related risks.

Mechanism of Action

Dual-Mechanism Pharmacodynamics

Cyclopan operates via a synchronized, dual-mechanism approach that influences both muscle tone and central signal processing. This involves the action of two distinct components, engaging a peripheral mechanism focused on autonomic regulation and a central mechanism focused on nociception signaling.

Spasmolysis through Cholinergic Pathway Blockade

The dicycloverine component acts primarily in the periphery, influencing pathways associated with heightened physiological responses within the gastrointestinal tract. It functions as a non-selective antagonist at Muscarinic Acetylcholine Receptors (M1, M2, M3) on smooth muscle cells, thereby suppressing the cholinergic signals that initiate involuntary spasms. This action modifies early molecular steps that shape systemic physiological outcomes, resulting in spasmolysis (relaxation) of the visceral muscle tissue.

Central Analgesia via Prostaglandin Modulation

The paracetamol component exerts its effect centrally by acting within domains involving enzyme-mediated signaling. It functions as an inhibitor of the Cyclooxygenase (COX) enzyme in the brain and spinal cord, which limits the production of Prostaglandin E2 ( PGE2). This influences the activity within targeted nociceptive pathways, raising the threshold for pain signal transmission and facilitating the modulation of afferent signal processing.

Dosage and Administration Information

How to use Cyclopan: Official Administration Guidelines

Cyclopan is a combination drug administered via defined protocols. The administration route, dosing schedule, and required adjustments are determined by the Dicycloverine and Paracetamol components.

Administration Scope	Official Requirement
Approved Routes	Administered by the Oral route (tablet or solution) and the Intramuscular (IM) route (injection). Intravenous (IV) administration is explicitly prohibited.
Standard Dosing	The Dicycloverine component is typically initiated at 20 mg four times a day (QID) for adults, potentially increasing to 40 mg QID. The maximum total daily intake is limited to 160 mg for the oral route.
Frequency/Timing	Doses are taken QID, ensuring a minimum interval of at least 4 hours is maintained between doses to comply with the Paracetamol component rules. The medicine may be taken with or without food.
Course Duration	IM use is restricted to a short duration, typically no more than one to two days. Oral administration should be discontinued if a therapeutic response is not evident after two weeks.
Population Rules	The drug is contraindicated in infants under six months of age. For older adults, a reduced initial dose of 10 mg QID is often advised. Patients with severe renal impairment require an extended minimum dosing interval of 6 hours.
Special Handling	Oral tablets must be swallowed whole. IM injection requires the procedural step of syringe aspiration before administration to confirm the needle is not placed intravascularly.

This official protocol defines a structured usage model governing dose ceilings, time limitations, and specific rules for administration technique.

Recent Clinical Evidence

Research evidence / Overview of studies for Cyclopan

The research into the combination medicine Cyclopan is based on studies of its two separate components: Dicycloverine (a spasmolytic agent) and Paracetamol (an analgesic agent). The evidence base describes patterns observed in clinical settings, but the overall certainty of the findings varies and research data for the specific fixed-dose combination (FDC) is still developing.

Evidence for use in Acute Spasmodic Pain Relief

The clinical evaluation for the use of Cyclopan in contexts involving acute, sudden visceral cramps and abdominal pain was studied by examining outcomes related to physical discomfort. Research has explored short-term symptom changes, primarily drawing from studies of the individual components and the broader class of antispasmodics. Studies measured "Total Pain Relief" (the clinical endpoint measured) and changes in Pain Intensity over very short, defined time intervals. Comparative evidence for the FDC is lacking, and the certainty remains low.

Evidence for use in Functional Gastrointestinal Discomfort

The Dicycloverine component was studied in research exploring conditions characterized by fluctuating or episodic manifestations, such as Irritable Bowel Syndrome (IBS). These studies explored symptom patterns in Adults and Young Adults. The research monitored outcomes reflecting daily functioning or activity level, including tracking the frequency and perceived severity of pain attacks. However, the available data for the Dicycloverine component itself is often reliant on older trials conducted decades ago. Due to this reliance, authoritative systematic reviews frequently indicate that the evidence quality varies and certainty remains low for the component’s evaluation in these conditions.

Gaps in the Research and Evidence Uncertainty

There are several limitations acknowledged in the research. Evidence quality varies across studies, with a significant amount of data for the spasmolytic component being ranked as having a "very low" quality by some regulatory-aligned reviews. Comparative evidence is lacking for the fixed-dose combination itself; the findings are largely inferred from the established pharmacological class of the two agents. Furthermore, data for specific populations like the pediatric population remain insufficient, and long-term outcomes are not well characterized.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Cyclopan (FAQ)

Q: How quickly should someone expect Cyclopan to start working?

Studies indicate that the Dicycloverine component typically reaches its peak concentration in the blood within approximately 60 to 90 minutes after oral intake. This timeframe describes the observation in clinical studies and is based on official product information.

Q: Does Cyclopan interact with common over-the-counter pain relievers?

The official label strictly restricts combining Cyclopan with any other medicine containing Acetaminophen (Paracetamol). This is due to the official restriction against cumulative exposure to Acetaminophen, which carries the risk of severe liver damage (hepatotoxicity). For other non-acetaminophen pain relievers, such as nonsteroidal anti-inflammatory drugs (NSAIDs), patients are directed to consult a healthcare provider, as these may also require monitoring or adjustment.

Q: Does taking Cyclopan affect driving ability?

Official labeling for the Dicycloverine component includes a warning that the drug may cause drowsiness or blurred vision. The official caution is for patients to avoid operating a motor vehicle or heavy machinery if they experience these effects, consistent with regulatory warnings.

Q: Is there a link between Cyclopan and changes in mood?

Adverse reactions reported for the Dicycloverine component include effects on the central nervous system (CNS). These effects can involve changes in mental state, such as agitation, confusion, or feelings of euphoria. Rarely, more serious effects like psychosis have been reported.

Q: Can Cyclopan cause problems with sleep?

The list of reported central nervous system side effects indicates that Cyclopan may affect sleep. Documented adverse reactions include both feelings of somnolence (drowsiness) and difficulty falling or staying asleep (insomnia).

Q: How long can a person continue to take Cyclopan?

Regulatory administration guidelines restrict the use of the intramuscular (IM) injection form to a short duration, typically 1 to 2 days. For oral administration, if the medicine is not providing a therapeutic response after two weeks, the official protocol advises discontinuing its use. Research evidence notes that long-term outcomes for this combination are not well characterized.

Q: Are there any specific foods to avoid when taking Cyclopan?

The medicine may be taken with or without food. Official guidance indicates that patients may continue their normal diet unless otherwise instructed by a healthcare professional.

Q: How is Cyclopan different from [another class of drug]?

Cyclopan is formally classified as a Spasmolytic Analgesic because it is a fixed-dose combination (FDC) that contains two active ingredients. This dual action is described as an approach that addresses both muscle relaxation (spasmolysis) and central pain relief (analgesia).

Q: How does Cyclopan compare to other older treatments for the condition?

The medicine's dual-action mechanism is based on a combination of anticholinergic spasm-relief and central prostaglandin modulation for pain. The findings used to assess this medicine are largely inferred from studies of its two separate drug classes, as direct comparative evidence for the fixed-dose combination itself is described as lacking.

Q: Does Cyclopan contain any ingredients that might cause an allergic reaction?

Yes. The official prescribing information lists prior hypersensitivity (severe allergic reaction) to Dicycloverine hydrochloride or to other inactive ingredients used in the formulation as a formal contraindication. The requirement is to identify all ingredients if a patient has known allergies.

Q: Why does the packaging for Cyclopan have a special warning label?

Official documentation details serious safety issues that warrant prominent warnings. These include the potential for severe liver damage (hepatotoxicity) from the Paracetamol component. Furthermore, the Dicycloverine component carries a specific risk of serious respiratory and central nervous system collapse, especially when administered to infants.

Q: What does the research say about Cyclopan and quality of life?

Research on functional gastrointestinal discomfort notes that some studies monitored outcomes reflecting daily functioning or activity level in adults and young adults. However, authoritative systematic reviews often indicate that the certainty of the findings in this area remains low.

Q: Is it true that Cyclopan can cause weight gain?

Official prescribing information does not list weight gain as a common or frequently reported adverse reaction. Conversely, one of the possible documented side effects for the Dicycloverine component is loss of appetite.

Q: What is the difference between Cyclopan and its generic version?

A generic version of the drug contains the exact same two active ingredients (Dicycloverine and Paracetamol) as the brand name product. Regulatory authorities require that generic products meet the same quality, purity, and effectiveness standards as the original drug.

Q: Can men and women take the same dose of Cyclopan?

The official prescribing information defines the standard recommended adult dosage based on factors such as age, weight, and existing conditions like renal impairment. The documentation does not specify separate dosages based on biological sex.

Q: What should be done if Cyclopan causes stomach upset?

Reported adverse reactions include stomach upset, nausea, and vomiting. Official labeling states that patients should report any unusual reactions or ongoing symptoms to their healthcare professional.

Q: What makes Cyclopan a controlled or scheduled medication, if applicable?

Cyclopan is a combination drug containing Dicycloverine and Paracetamol. This combination is not classified as a controlled substance by the Drug Enforcement Administration (DEA) in the United States.

Q: Can Cyclopan be taken if someone is already on blood pressure medication?

Official labeling notes a potential for interaction when Cyclopan is taken with certain blood pressure medicines, specifically thiazide diuretics. This interaction may increase the risk of side effects such as hypotension (low blood pressure) or dehydration.

Q: Is there a typical time of day that Cyclopan is usually taken?

Official dosing instructions direct the medicine to be taken four times a day (QID). Regulatory guidance requires that a minimum 4-hour interval be maintained between doses, but does not specify a preferred time of day for overall therapy.

Q: What does 'contraindicated' mean in the context of Cyclopan?

The term 'contraindicated' is regulatory language meaning that the medication should never be used in a specific patient group or under certain medical conditions. The risk of harm in a contraindicated situation is described as significantly greater than any potential benefit.

Q: What kind of monitoring (like blood work) is needed while on Cyclopan?

Monitoring is typically associated with the risk of severe liver damage (hepatotoxicity) from the Paracetamol component, especially with long-term use. This may involve blood tests, such as liver function tests, conducted according to the healthcare professional’s determination.

Q: Why is Cyclopan often prescribed when other medicines haven't worked?

The drug's therapeutic purpose is defined by its dual mechanism: one component acts directly on the muscle spasm while the other provides centralized relief from the pain sensation. This combined pharmacological approach differs from treatment options that rely on a single agent.

Q: How long does Cyclopan stay in the body after the last dose?

The duration a medicine stays in the body is often measured by its elimination half-life. Official pharmacokinetics data indicates that the Dicycloverine component has a mean elimination half-life of approximately 1.8 hours.

Q: Does Cyclopan affect appetite?

Yes, official safety information indicates that the Dicycloverine component may affect appetite. The list of documented side effects includes loss of appetite.

Q: Is it normal to feel anxious when starting Cyclopan?

Reported central nervous system adverse reactions include a feeling of agitation as a possible side effect. However, the official documentation also notes reports of decreased anxiety in some cases.

How should Cyclopan be stored and disposed of?

The storage and disposal of Cyclopan (Dicycloverine/Paracetamol) must follow official regulatory mandates to ensure safety and integrity.

Storage Requirements

Cyclopan must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with brief excursions allowed up to 30 C. The product must be kept in its original, tight, light-resistant container to protect it from moisture and light. For liquid forms, the instruction do not freeze often applies to maintain product stability.

Protection and Disposal

The regulatory label mandates the statement to keep out of the sight and reach of children, typically requiring a child-resistant closure. Disposal of unused or expired medicine should primarily use a formal drug take-back program or authorized collection site. If a take-back option is unavailable, the FDA's guidance recommends mixing the medicine with an unappealing substance, sealing it in a container, and discarding it in the household trash, avoiding sinks or toilets.

Cyclopan